Impact Capital Partners LLC Acquires Shares of 1,333 Laboratory Co. of America Holdings (NYSE:LH)

Impact Capital Partners LLC acquired a new stake in Laboratory Co. of America Holdings (NYSE:LH) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,333 shares of the medical research company’s stock, valued at approximately $306,000.

A number of other hedge funds have also recently modified their holdings of the company. Fore Capital LLC purchased a new position in shares of Laboratory Co. of America during the fourth quarter valued at about $1,353,000. Skandinaviska Enskilda Banken AB publ increased its position in shares of Laboratory Co. of America by 11.1% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 17,975 shares of the medical research company’s stock valued at $4,114,000 after buying an additional 1,800 shares during the period. Great Lakes Advisors LLC increased its position in shares of Laboratory Co. of America by 675.2% during the fourth quarter. Great Lakes Advisors LLC now owns 27,038 shares of the medical research company’s stock valued at $6,200,000 after buying an additional 23,550 shares during the period. Farther Finance Advisors LLC increased its position in shares of Laboratory Co. of America by 122.2% during the fourth quarter. Farther Finance Advisors LLC now owns 3,077 shares of the medical research company’s stock valued at $706,000 after buying an additional 1,692 shares during the period. Finally, Sequoia Financial Advisors LLC increased its position in shares of Laboratory Co. of America by 0.4% during the fourth quarter. Sequoia Financial Advisors LLC now owns 135,888 shares of the medical research company’s stock valued at $31,162,000 after buying an additional 475 shares during the period. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Trading Down 0.6 %

Shares of NYSE LH opened at $235.45 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. The firm’s 50 day moving average price is $244.47 and its 200-day moving average price is $233.94. Laboratory Co. of America Holdings has a 52-week low of $191.97 and a 52-week high of $258.59. The company has a market cap of $19.71 billion, a PE ratio of 26.69, a P/E/G ratio of 1.71 and a beta of 1.12.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. On average, equities research analysts expect that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th were issued a dividend of $0.72 per share. The ex-dividend date was Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.22%. Laboratory Co. of America’s dividend payout ratio is currently 32.65%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Citigroup upgraded shares of Laboratory Co. of America from a “neutral” rating to a “buy” rating and boosted their price target for the company from $250.00 to $300.00 in a research report on Tuesday, March 4th. UBS Group dropped their price objective on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Bank of America boosted their price objective on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Morgan Stanley boosted their price objective on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Finally, StockNews.com raised shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $268.38.

Insider Buying and Selling at Laboratory Co. of America

In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $235,000.00. Following the completion of the sale, the director now directly owns 12,722 shares of the company’s stock, valued at approximately $2,989,670. This represents a 7.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 1,314 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $251.30, for a total transaction of $330,208.20. Following the sale, the executive vice president now directly owns 2,171 shares of the company’s stock, valued at approximately $545,572.30. This represents a 37.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,500 shares of company stock valued at $3,577,572. Insiders own 0.85% of the company’s stock.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.